CLN11 GRN Progranulin Deficiency Care Tech Platform Monitoring Guide 2026

CLN11 disease — GRN-related adult-onset neuronal ceroid lipofuscinosis — is a rare lysosomal storage disorder caused by biallelic pathogenic variants in GRN, the gene encoding Granulin, also known as Progranulin. Progranulin is a multifunctional secreted glycoprotein that operates both extracellularly — as a growth factor, anti-inflammatory cytokine, and wound healing mediator — and intracellularly, after trafficking to the lysosome, where cathepsin B and D cleave it into individual granulin peptides. These granulins are essential for normal lysosomal function: they regulate cathepsin D activity, support lysosomal biogenesis via TFEB activation, and maintain lysosomal membrane integrity. GRN deficiency therefore causes lysosomal dysfunction, secondary cathepsin D impairment, accumulation of autofluorescent ceroid lipofuscin storage material, and TDP-43 proteinopathy — the same cytoplasmic TDP-43 inclusions seen in frontotemporal dementia and amyotrophic lateral sclerosis.

This molecular pathology places CLN11 at the intersection of two disease worlds. Heterozygous null variants in GRN cause frontotemporal dementia (FTD-GRN) — a relatively common adult neurodegenerative disease. Homozygous or compound heterozygous GRN null variants cause CLN11 — a rare lysosomal storage disorder presenting in the teens to thirties. A single family can thus harbor both CLN11 (in an affected homozygous individual) and elevated FTD-GRN risk (in heterozygous carrier parents and siblings). This unique genetic architecture has profound implications for family counseling and for the shared research infrastructure connecting the NCL and frontotemporal dementia fields.

CLN11 patients typically present with progressive myoclonic epilepsy (PME) in their teens to thirties — action myoclonus, stimulus-sensitive myoclonus, cerebellar ataxia, and eventual dementia. Unlike Kufs disease (CLN4), CLN11 involves the retinal pigment epithelium, causing progressive visual failure as part of the disease course. There is no approved disease-modifying therapy. Progranulin gene therapy is in clinical development for FTD-GRN and may benefit CLN11; investigational latozinemab (anti-PGRN antibody) is under study. Seizure management with valproate, levetiracetam, and clonazepam forms the primary symptomatic approach.

Why Monitoring Matters for CLN11 Care Platforms

CLN11 disease creates a care ecosystem that spans adult epilepsy, ophthalmology, cognitive neurology, and genetics — while simultaneously intersecting with the much larger FTD-GRN research community. The platforms supporting CLN11 care must coordinate across these discipline boundaries, and because the condition is so rare, there are no dedicated CLN11-specific scheduling systems — patients rely on general adult epilepsy, neurology, ophthalmology, and genetics infrastructure.

The Association for Frontotemporal Degeneration (AFTD) GRN research platforms and the BDSRA CLN11 registry together provide the community infrastructure that connects the small CLN11 patient population with clinical expertise and research opportunities. These platforms also support the heterozygous FTD-GRN carrier relatives of CLN11 patients — a population that may be monitored through the same family clinic infrastructure. Vigilmon's continuous monitoring ensures that these rare community resources remain consistently available, particularly during the vulnerable period when families are navigating both the CLN11 diagnosis and the FTD-GRN implications for carrier relatives.

Progressive Myoclonic Epilepsy Monitoring Scheduling Tools

PME is the defining neurological feature of CLN11 disease and the primary driver of acute safety risk. The monthly seizure diary monitoring and every-6-to-12-month EEG surveillance schedule require reliable scheduling infrastructure sustained over a disease course of decades.

Critical monitoring targets for epilepsy monitoring platforms:

Seizure diary patient portal: Monthly seizure diary and myoclonus severity scaling review between clinic visits is the backbone of PME management in CLN11. Monitor the seizure diary submission portal at 5-minute check intervals, including the mobile application API endpoints that receive diary entries from patients. Silent failures at this endpoint allow myoclonus data gaps to accumulate undetected, obscuring disease progression between clinic visits.
EEG scheduling system: EEG every 6 to 12 months tracks PME pattern evolution, anti-epileptic response, and photosensitivity. Adult epilepsy EEG scheduling platforms should be monitored at 2-minute intervals during clinic hours with SSL certificate expiry alerts set at 60 days.
Anti-epileptic drug level tracking platform: Valproate monitoring requires regular serum levels. The ordering and results delivery platform for therapeutic drug monitoring should be monitored for uptime and API response time to the neurologist dashboard — dose adjustment decisions depend on timely results delivery.
Neurology assessment scheduling system: Adult neurology assessment every 6 months tracks disease progression. Monitor the scheduling portal for uptime and the appointment reminder delivery API, since PME management in adults is heavily dependent on consistent follow-up adherence.

Visual Surveillance Scheduling Systems

CLN11 disease, unlike CLN4/Kufs disease, involves the retinal pigment epithelium and causes progressive visual failure. The ophthalmologic monitoring schedule — every 6 months — must be reliably maintained alongside the epilepsy monitoring infrastructure.

Visual monitoring platform targets:

Ophthalmology scheduling portal: Six-monthly ophthalmology visits including electroretinogram and visual field testing track retinal CLN11 involvement. Monitor the ophthalmology scheduling portal at 5-minute check intervals. ERG and visual field slots at specialist centers are scarce — scheduling failures that displace appointments can create 12-month gaps in retinal surveillance.
Electroretinogram scheduling and reporting system: ERG amplitude monitoring is both a diagnostic marker (confirming retinal involvement) and a disease progression endpoint. Monitor the ERG scheduling platform and the electrophysiology reporting interface with attention to the integration endpoint that delivers ERG results to the neurologist coordinating combined epilepsy-vision care.
Low vision rehabilitation scheduling platform: Progressive visual loss in CLN11 requires low vision rehabilitation planning beginning well before functional vision is lost. Monitor the low vision clinic scheduling portal for uptime and appointment reminder delivery API reliability.
MRI brain scheduling system: MRI brain every 12 to 24 months documents the trajectory of cerebellar and cortical atrophy. Monitor the MRI scheduling interface with 5-minute check intervals and 60-day SSL certificate expiry alerts.

Progranulin Biomarker Monitoring Scheduling Systems

Serum progranulin protein level is a quantitative biomarker of GRN null variant status — homozygous CLN11 patients have extremely low progranulin, while heterozygous FTD-GRN carriers have approximately half-normal levels. This biomarker platform serves both affected individuals and carrier family members.

Biomarker platform monitoring targets:

Serum progranulin scheduling and results platform: Annual serum progranulin protein level monitoring provides quantitative tracking of progranulin status and, in the context of clinical trials, serves as a pharmacodynamic endpoint for progranulin replacement therapies. Monitor the scheduling and results delivery platform for this specialized assay with 5-minute check intervals and a performance threshold of 6 seconds for the results delivery interface.
Lysosomal enzyme panel scheduling system: Comprehensive lysosomal enzyme panels — including cathepsin D activity, which is secondarily impaired in progranulin deficiency — should be monitored annually. Monitor the specialized laboratory scheduling platform for uptime and the results API.
Family progranulin screening scheduling portal: First-degree relatives of CLN11 patients are obligate heterozygous GRN carriers and face elevated FTD-GRN risk. Family progranulin level screening scheduling — coordinating both the CLN11 proband's family and the broader genetics team — requires a reliable portal. Monitor for uptime and appointment confirmation delivery.
Neuropsychological assessment scheduling system: Annual standardized neuropsychological assessment tracks cognitive decline in CLN11 patients and, separately, monitors carrier relatives who may be developing early FTD-GRN features. Monitor scheduling platforms at neuropsychology programs with 5-minute check intervals.

Family Neurology Clinic and FTD-GRN Coordination Portals

The unique genetic architecture of CLN11 — where a single family may have a CLN11-affected homozygous individual and FTD-GRN-risk heterozygous relatives — requires care infrastructure that spans the NCL and frontotemporal dementia disciplines. Dedicated family neurology clinic portals coordinating both conditions within the same family are rare and valuable.

Family coordination platform monitoring targets:

Family NCL-FTD neurology clinic portal: The primary coordination interface for a family clinic serving both CLN11 and FTD-GRN should be monitored at 2-minute intervals with dual-channel alerting (email and SMS) to the clinic coordinator. Pre-define escalation paths for outages exceeding 15 minutes during scheduled family clinic days.
FTD-GRN carrier monitoring scheduling system: Carrier relatives of CLN11 patients require periodic neuropsychological monitoring as they approach the age of FTD-GRN risk. Monitor the carrier monitoring scheduling portal for uptime and integration with the family neurology clinic's primary coordination system.
AFTD GRN research platform: The Association for Frontotemporal Degeneration's GRN-specific research portal connects carrier relatives with longitudinal research studies and clinical trial information relevant to FTD-GRN. Monitor this platform for availability from the family clinic coordination perspective, with 5-minute check intervals.
BDSRA CLN11 registry portal: The BDSRA CLN11 registry provides the primary data infrastructure for CLN11 natural history research. Monitor the registry submission and data access portal with 5-minute check intervals and SSL certificate expiry alerts set at 60 days.

Genetic Counseling and Clinical Trial Scheduling Platforms

The GRN inheritance architecture creates complex genetic counseling requirements: parents of a CLN11 patient are obligate heterozygous carriers facing FTD-GRN risk themselves, and siblings may be either carriers or homozygous affected. Clinical trial enrollment for progranulin replacement therapies may be relevant to both CLN11 patients and FTD-GRN carrier relatives.

Genetic counseling and trial platform monitoring targets:

Genetic counseling scheduling portal: Genetic counseling is essential for all CLN11 families — addressing biallelic GRN inheritance, the FTD-GRN risk of carrier relatives, prenatal diagnosis options, and reproductive alternatives. Monitor the genetics clinic scheduling portal for uptime and appointment confirmation delivery.
FTD-GRN risk counseling scheduling system: Carrier parent and sibling FTD-GRN risk counseling requires dedicated scheduling coordination within or alongside the genetics clinic. Monitor the scheduling interface used to coordinate carrier counseling appointments with 5-minute check intervals.
Clinical trial enrollment scheduling platform: Progranulin gene therapy and latozinemab trials may enroll both CLN11 homozygotes and FTD-GRN heterozygotes. The trial enrollment and screening scheduling portal — potentially shared between NCL and FTD trial infrastructure — should be monitored with immediate alerting and 5-minute check intervals. Enrollment windows in rare disease trials are narrow and missed screenings can permanently exclude eligible participants.
PGT-M coordination platform: Preimplantation genetic testing for monogenic disease offers CLN11 families a reproductive alternative. Monitor the PGT-M referral and cycle coordination platform with 5-minute check intervals and SSL certificate expiry monitoring.
Reproductive counseling scheduling portal: Reproductive options counseling — covering prenatal diagnosis, PGT-M, and the implications of GRN carrier status — requires a reliable scheduling interface. Monitor for uptime and appointment reminder delivery reliability.

Alerting Strategy for CLN11 Care Technology

Vigilmon's escalation configuration for CLN11 platforms should reflect the dual NCL and FTD-GRN care demands:

P1 — Seizure diary portal, primary family neurology coordination portal, or trial enrollment portal down: Immediate alerting to the clinic nurse coordinator; 30-minute escalation to the attending neurologist during active PME management phases; documented backup procedure activated.
P2 — Ophthalmology, EEG, progranulin assay, or neuropsychology scheduling systems down: Email and SMS to scheduling coordinator; 1-hour escalation during clinic hours; next-business-day escalation after hours.
P3 — AFTD/BDSRA registry platforms, family carrier monitoring systems, or genetic counseling portals down: Email to platform administrator; 4-hour escalation window during business hours.

Status Page Configuration for CLN11 Care Programs

A shared Vigilmon status page for CLN11 programs should separate components by clinical domain: PME and seizure monitoring, visual surveillance, progranulin biomarker platforms, family neurology and FTD-GRN coordination, and genetic counseling and trial enrollment. This structure allows the epilepsy team, the ophthalmology team, and the genetics-FTD coordination team to each quickly identify whether failures are isolated to their domain.

Pre-draft incident communication templates for the clinical trial enrollment portal — where communication to families navigating both CLN11 management and trial eligibility windows requires precision and timeliness.

Families living with CLN11 disease navigate a condition that reaches across the neurology of lysosomal storage disease into the world of frontotemporal dementia — simultaneously managing a rare NCL diagnosis and the FTD-GRN implications for carriers they love. The technology platforms supporting this uniquely complex family journey must be consistently reliable, and Vigilmon provides the monitoring infrastructure to ensure that reliability is visible, measured, and maintained.

Vigilmon provides uptime, latency, and availability monitoring for healthcare technology platforms. Continuous monitoring of CLN11 care platforms supports the coordinated, reliable access that GRN progranulin deficiency families need across the intersecting worlds of adult NCL disease and frontotemporal dementia research.